IP Library Granted Patent US 8,728,138
Granted Patent B2
US 8,728,138 · App. 13/765,532 · Granted May 20, 2014

Methods for thermally-induced renal neuromodulation

Inventors: Denise Zarins (Saratoga, CA); Nicolas Zadno (Fremont, CA); Benjamin J. Clark (Redwood City, CA); Erik Thai (San Jose, CA); Howard R. Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,138
App. No.
13/765,532
Granted
May 20, 2014
Kind
B2
Abstract

Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.

Claims (30)

1. A method of treating a human patient diagnosed with a cardio-renal disease or disorder, the method comprising:

intravascularly delivering a device to a vicinity of a neural fiber associated with renal function of the patient; and

thermally inhibiting neural communication along the neural fiber with the device.

2. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises thermally inhibiting afferent neural communication along the neural fiber with the device.

3. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises thermally inhibiting efferent neural communication along the neural fiber with the device.

4. The method of claim 1 wherein intravascularly delivering a device to a vicinity of a neural fiber associated with renal function comprises intravascularly delivering the device via a renal blood vessel to a position proximate to the neural fiber.

5. The method of claim 1 wherein intravascularly delivering the device via a blood vessel to a position proximate to the neural fiber comprises intravascularly positioning the device in contact with a wall of the blood vessel proximate to the neural fiber.

6. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises at least partially ablating the neural fiber with the device.

7. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises thermally altering the neural fiber using at least one of non-ablative heating, ablative heating, cooling, and freezing.

8. The method of claim 1 , further comprising removing the device from the patient after thermally inhibiting neural communication along the neural fiber.

9. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises delivering an energy field to the neural fiber via the device.

10. The method of claim 9 wherein delivering an energy field to the neural fiber via the device comprises delivering radiofrequency energy via the device.

11. The method of claim 9 wherein delivering an energy field to the neural fiber via the device comprises delivering microwave energy via the device.

12. The method of claim 9 wherein delivering an energy field to the neural fiber via the device comprises delivering ultrasound energy via the device.

13. The method of claim 12 wherein delivering ultrasound energy via the device comprises delivering high intensity focused ultrasound energy via the device.

14. The method of claim 9 wherein delivering an energy field to the neural fiber via the device comprises delivering laser energy via the device.

15. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises reducing neural activity via cooling the neural fiber.

16. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises causing freezing injury to the neural fiber.

17. The method of claim 1 wherein thermally inhibiting neural communication along the neural fiber with the device comprises delivering a thermal fluid via the device.

18. A method of treating a human patient diagnosed with a medical condition, the method comprising:

positioning a device in proximity to a neural pathway that carries nerve signals to and from a kidney of the patient; and

thermally inhibiting the nerve signals across the neural pathway with the device,

wherein thermally inhibiting the nerve signals across the neural pathway results in a therapeutically beneficial reduction in renal sympathetic nerve activity of the patient.

19. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with hypertension.

20. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with chronic heart failure.

21. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with a condition associated with diabetes.

22. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with kidney disease.

23. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with chronic renal failure.

24. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with acute myocardial infarction.

25. The method of claim 18 wherein treating a human patient diagnosed with a medical condition comprises treating a human patient diagnosed with atrial fibrillation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2013
From: DEMARAIS, DENISE; ZADNO, NICOLAS; CLARK, BENJAMIN J.; THAI, ERIK; LEVIN, HOWARD R.; GELFAND, MARK
To: ARDIAN, INC.
Reel/Frame 031414/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030531/0717 →
CHANGE OF NAME Recorded Jun 3, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030531/0816 →
Continuity (13)
Continuation 12700524 · Feb 4, 2010
Continuation 11840142 · Aug 16, 2007
Continuation 11504117 · Aug 14, 2006
Continuation In Part 10408665 · Apr 8, 2003
Continuation In Part 11189563 · Jul 25, 2005
Continuation In Part 11129765 · May 13, 2005
Provisional Application 60816999 · Jun 28, 2006
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Provisional Application 60616254 · Oct 5, 2004
Provisional Application 60624793 · Nov 2, 2004
Related Publication 20130158442A1 · Jun 20, 2013